Lupin receives FDA OK for generic Trokendi
Topiramate extended-release capsules are indicated for the treatment of partial-onset or primary generalized tonic-clonic seizures in certain patients.
Lupin has received approval from the Food and Drug Administration for topiramate extended-release capsules, 25 mg, 50 mg, 100 mg and 200 mg, which is a generic equivalent of Supernus Pharmaceuticals’ Trokendi.
The product will be manufactured at Lupin’s Pithampur facility in India.
[Read more: Lupin receives FDA nod for 3 generics]
Topiramate extended-release capsules are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 6 years of age and older.
Topiramate extended-release capsules had a market value of roughly $253 million, per IQVIA May 2024 data.
[Read more: Lupin receives FDA OK for generic Banzel]